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Abstract
As a severe chronic metabolic disease and autoimmune disorder, type 1 diabetes (T1D) affects millions of people world-
wide. Recent advances in antigen-based immunotherapy have provided a great opportunity for further treating T1D with a
high degree of selectivity. It is reported that MHC class II I-A
g7 in the non-obese diabetic (NOD) mouse and human HLA-DQ8
are strongly linked to susceptibility to T1D. Thus, the identification of new I-A
g7 and HLA-DQ8 epitopes would be of great
help to further experimental and biomedical manipulation efforts. In this study, a novel GPS-MBA (MHC Binding Analyzer)
software package was developed for the prediction of I-A
g7 and HLA-DQ8 epitopes. Using experimentally identified
epitopes as the training data sets, a previously developed GPS (Group-based Prediction System) algorithm was adopted and
improved. By extensive evaluation and comparison, the GPS-MBA performance was found to be much better than other
tools of this type. With this powerful tool, we predicted a number of potentially new I-A
g7 and HLA-DQ8 epitopes.
Furthermore, we designed a T1D epitope database (TEDB) for all of the experimentally identified and predicted T1D-
associated epitopes. Taken together, this computational prediction result and analysis provides a starting point for further
experimental considerations, and GPS-MBA is demonstrated to be a useful tool for generating starting information for
experimentalists. The GPS-MBA is freely accessible for academic researchers at: http://mba.biocuckoo.org.
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Introduction
Type 1 diabetes (Diabetes mellitus type 1, T1D or T1DM) is a
severe chronic autoimmune disease with a relapsing-remitting
course that is characterized by the insidious loss of self-tolerance
and progressive destruction of insulin-producing pancreatic b-cells
in the islets of Langerhans, with the presence of overt
hyperglycemia at the time of clinical diagnosis [1–7]. The
incidence and prevalence of T1D has dramatically increased
worldwide over the past several decades, and the onset and
development of T1D is believed to be controlled by both genetic
and environmental factors [1–5,8]. The cumulative analysis has
revealed that a variety of immune cell types, including CD4
+,
CD8
+ T cells, macrophages and dendritic cells (DCs) are involved
in b-cell death, and CD4
+ T cells play the predominant role in the
overall T1D pathology [1,2,8]. Thus, the development of
immunoregulatory therapeutic approaches has come to be an
urgent demand for preventing, treating or even curing T1D [1–7].
Besides immunosuppressive drugs and antibody-based immu-
notherapies, antigen-based ‘‘tolerogenic’’ immunotherapy has
attracted considerable attention as a third-generation approach,
particularly for its highly selective targeting of aberrant T cells
[1–6]. It was demonstrated that the MHC class II haplotype, I-A
g7,
is strongly linked to susceptibility to T1D in the non-obese diabetic
(NOD) mouse [9–11]. Similar linkage to the human HLA-DQ8
molecule, I-A
g7 is expressed by DCs to present b-cell epitopes from
certain well-defined autoantigens, including insulin, glutamic acid
decarboxylase (GAD) and insulinoma antigen 2 (IA-2) [1–6,8].
These epitopes areusually composed of 10 to 30 amino acids, with a
9-amino acid core sequence for I-A
g7/HLA-DQ8 and T-cell
receptor (TCR) binding [9–11]. In this regard, identification of I-
A
g7/HLA-DQ8 epitopesisfundamentalforanunderstanding ofthe
molecular mechanisms of T1D and the improved design of
immunotherapeutic peptides. In 2009, the first-in-human beings
Phase I clinical study reported that proinsulin peptide injection is
both well tolerated and safe [12]. Recently, a C-peptide deduced
from the GAD 65 isoform has generated promising results in Phase
II trials, and three Phase III trials are still ongoing [1,2,5].
As a complement to labor-intensive and time-consuming
experimental assays, the in silico prediction of MHC-binding
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information for the purposes of biomedical design [13,14] (see also
http://mba.biocuckoo.org/ links.php). For example, the predic-
tion results of SYFPEITHI [15] and BIMAS [16] were successfully
used for the experimental identification of novel MHC class I
epitopes derived from type 1 diabetes autoantigens [17–19]. Since
I-A
g7 is the only expressed MHC class II molecule in the NOD
mouse [9,10], additional efforts have subsequently been expended
on the prediction of I-A
g7 or HLA-DQ8 epitopes [20–23]. In
2006, Rajapakse et al. developed the first online server of
PRED
NOD for the prediction of I-A
g7, and the two MHC class I
molecules K
d and D
b binding peptides in the NOD mouse [20].
They subsequently refined the predictor using multi-objective
evolutionary algorithms (MOEA) [23]. Chang et al. used an
expectation-maximization alignment algorithm to design compu-
tational programs for the prediction of I-A
g7 [21] and HLA-DQ8
[22] epitopes, respectively. Furthermore, the two integrative tools
of MHC2Pred [24,25] and RANKPEP [26] also include
predictors for I-A
g7 and HLA-DQ8, although they were developed
for the comprehensive prediction of a variety of MHC class I and/
or II binding peptides. Currently, although a number of
computational studies have been performed, only MHC2Pred
[24,25] and RANKPEP [26] are accessible over the internet.
In this work, we developed a novel GPS-MBA software package
for the prediction of I-A
g7 and HLA-DQ8. The experimentally
identified epitopes were obtained from the scientific literature, and
a modified Gibbs sampling approach was adopted to determine
the core nonamers in these epitopes. For training and prediction, a
refined GPS algorithm [27,28] was used. By extensive evaluation
and comparison, the prediction performance of GPS-MBA was
shown to be highly promising and much better than the other tools
currently in use. Moreover, by cross-evaluation using the HLA-
DQ8 predictor in GPS-MBA to predict the I-A
g7 epitopes and vice
versa, the results show that I-A
g7 and HLA-DQ8 recognize highly
similar peptide profiles. With this powerful tool, we predicted
potentially novel I-A
g7 and HLA-DQ8 binding peptides from
T1D-associated epitopes, which bind to other types of MHC
molecules. All of the experimentally identified T1D antigens
together with their epitopes were absorbed into TEDB 1.0. The ab
initio predicted epitopes were also provided. Taken together, the
prediction and analysis results are helpful for further experimental
investigation, and the GPS-MBA can serve as a practically useful
adjunct program for experimentalists. The online service and local
packages of GPS-MBA 1.0 were implemented in JAVA and freely
accessible for academic research purposes at: http://mba.
biocuckoo.org.
Methods
Data preparation
A search of the scientific literature from PubMed (before Sept.
20
th, 2011) with the keywords ‘‘I-A
g7 peptide’’, ‘‘HLA-DQ8
peptide’’, or ‘‘Type 1 diabetes epitope’’, we collected 318
experimentally verified and naturally processed mouse I-A
g7
binding peptides in 177 proteins, and 134 human HLA-DQ8
epitopes from 84 proteins (Table 1). Additional keywords were
tried, but the data set was not changed. The protein sequences
were retrieved from the UniProt database (http://www.uniprot.
org/uniprot/).
In our data set, the length of most of the epitopes varies from
9,30aa. Thus, we adopted a refined Gibbs sampling approach
[29,30] to determine the 9aa core peptides, and obtained 301
unique nonamer epitopes for the I-A
g7 and 127 HLA-DQ8 core
peptides for training. We also prepared positive (+) and negative
(2) data sets for testing. The 318 I-A
g7 and 134 HLA-DQ8
epitopes of known length were regarded as the (+) set. If at least
one predicted nonamer is fully located in the epitope region, the
epitope is predicted as a positive hit. To avoid any bias, all of the
9-mer lengths of the same proteins which were either not covered
or not fully covered by the original epitopes were taken to be the
(2) set.
By further literature review, we collected 203 T1D-associated
epitopes in 25 proteins which have the potential to be recognized
by other types of MHC or unknown molecules (Table 1).
Performance evaluation
As previously described [27,28], we used the four measurements
of sensitivity (Sn), specificity (Sp), accuracy (Ac) and Mathew’s
Correlation Coefficient (MCC). The measurements were defined as
below:
Sn~
TP
TPzFN
, Sp~
TN
TNzFP
, Ac~
TPzTN
TPzFNzTNzFP
and
MCC~
(TP|TN){(FN|FP)
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
(TPzFN)|(TNzFP)|(TPzFP)|(TNzFN)
p :
To evaluate the prediction performance and robustness, the
leave-one-out (LOO) validation and 4-, 6-, 8- and 10-fold (n-fold)
cross-validations were performed. In the LOO validation, each
core nonamer in the data set was picked out in turn as an
independent test sample, and all the remaining core nonamers
were regarded as training data. This process was repeated until
each nonamer was used as test data one time. In the n-fold cross-
validation, all the (+) core nonamers and (2) nonamers were
mixed and then divided equally into n parts, keeping the same
distribution of (+) and (2) nonamers in each part. Then n-1 parts
were merged into a training data set while the remnant part was
taken as a testing data set. This process was repeated 20 times and
the average performance of n-fold cross-validation was computed.
Furthermore, the Receiver Operating Characteristic (ROC)
curves were drawn, and AROC (area under ROC) values were
calculated.
The algorithm
Previously, we developed a series of GPS algorithms for the
prediction of post-translational modification (PTM) sites in
proteins [27,28]. For the prediction of the I-A
g7 and HLA-DQ8
binding peptides, we used the original method to develop a new
Table 1. The statistical data on the experimentally validated
epitopes collected in this study.
Experimental data set Protein Epitope
a Core 9-mer
b
Mouse I-A
g7 177 318 301
Human HLA-DQ8 84 134 127
Other T1D-associated 25 203
Total 245 623
aEpitope, the number of original epitopes;
bCore 9-mer, the number of nonamer core peptides derived from the adapted
Gibbs sampling procedure.
doi:10.1371/journal.pone.0033884.t001
Prediction of I-Ag7 and HLA-DQ8 Binding Peptides
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and performance improvement.
The basic hypothesis behind the scoring strategy is that similarly
short peptides would exhibit similar 3D structures and biochemical
properties [27,28]. Thus, we can directly use an amino acid
substitution matrix, e.g., BLOSUM62, to calculate the similarity
between two 9-mer peptides A and B as:
SA ,B ðÞ ~
X
1ƒiƒ9
Score A i ½  ,Bi ½  ðÞ
Score(A[i], B[i]) denotes the substitution score of the two amino
acids of A[i] and B[i] in the BLOSUM62 at the position i.I fS(A,
B),0, we redefined it as S(A, B)=0. A given nonapeptide is then
compared with each of the 9aa core peptides from the training
data in a pairwise manner to calculate the similarity score. The
average value of the substitution scores is regarded as the final
score.
The performance improvement procedure is comprised of two
steps, weight training (WT) and matrix mutation (MaM). To
evaluate the degree of performance improvement, we calculated
the scores for all sites of the training data set in each time. By
gradually increasing the threshold, we computed the Sn, Sp, Ac and
MCC under different cut-off values. Thus, we fixed the Sp at 90%
and compared the Sn values of the LOO validation.
1) Weight training (WT). In this step, the substitution score
between the two 9-mer peptides A and B was updated as follows:
S’ A,B ðÞ ~
X
1ƒiƒ9
wiScore A i ½  ,Bi ½  ðÞ
Initially, the weight of each position was defined as 1. The wi
value is the weight of the position i. Again, if S9(A, B)i s,0, we
redefined it as S9(A, B)=0. Then we randomly picked out the
weight of any position for +1o r21 and re-computed the LOO
result. The manipulation was adopted if the Sn value was
increased. This process was continued until the Sn value did not
increase any further.
2) Matrix mutation (MaM). The aim of this step is to
generate an optimal or near-optimal scoring matrix from an initial
matrix. We re-calculated the LOO result to improve the Sn value
by randomly picking out an element of the BLOSUM62 matrix
for +1o r21. The process was repeated until convergence was
reached. Selecting a different initial matrix, e.g., BLOSUM45 will
generate a convergent result if the training time is sufficient (Data
not shown).
Implementation of the online service and local packages
The online service and local packages of GPS-MBA 1.0 were
implemented in JAVA. For the online service, we tested GPS-
MBA 1.0 on a variety of internet browsers, including Internet
Explorer 6.0, 8.0 and 9.0, Mozilla Firefox 8.0 and Google Chrome
under the Windows XP and Windows 7 Operating System (OS),
Mozilla Firefox 8.0 and Google Chrome under Fedora Core 15
and Ubuntu 10.04 LTS (Linux), and Safari 5.1.1 under Apple
Mac OS 610.5 (Leopard) and 10.7 (Lion). For the Windows and
Linux systems, the latest version of Java Runtime Environment
(JRE) package (Java SE 5.0 or later versions) should be pre-
installed. However, for Mac OS, GPS-MBA 1.0 can be directly
used without any additional packages. For convenience, we also
developed local packages of GPS-MBA 1.0 which support the
three major Operating Systems Windows, Linux and Mac OS X.
Results
Determination of the core nonamers from the I-A
g7 and
HLA-DQ8 epitopes
From the scientific literature, we collected 318 naturally
processed I-A
g7 epitopes and 134 HLA-DQ8 binding peptides of
various lengths from 8,30aa (Table 1). The prerequisite for the
usage of GPS algorithm is that the length of peptides must be fixed
and identical in the training data set [27,28]. Previously,
experimental analyses had suggested that the I-A
g7 and HLA-
DQ8 epitopes contain the 9aa core sequences needed for
recognition and binding [9–11]. Since there is only one epitope
with 8aa, we added one residue upstream and one residue
downstream for the 8aa peptide so as to form a decapeptide. Then
we used an adapted Gibbs sampling approach to determine the
core nonamers of the I-A
g7 (Table S1) and HLA-DQ8 epitopes
(Table S2) [29–31].
Given a set of N epitopes S1,… ,SN, we sought to identify the
most probable nonapeptides that were mutually present in both
epitopes (Figure 1). First, one 9-mer length per epitope as P1,… ,
PN was randomly selected, while we randomly singled out one
epitope Si together with its nonapeptide Pi (Figure 1). Then we
calculated the similarity scores for all of the 9-mer peptides
sequentially in Si, as described below:
Score PiÞ ð ~
P
1ƒiƒN,j=i
S(Pi,Pj)
N{1
The Score(Pi) is the average final similarity score compared with
the other nonamers, while S(Pi, Pj) is the similarity score between Pi
and Pj. The 9-mer with the maximal Score(Pi) is sampled and then
updated to the new nonapeptide Pi (Figure 1). Such a sampling
procedure was iteratively repeated until convergence was attained
(Figure 1). Ultimately, the redundant 9-mer core peptides were
made clearly evident (Table 1, Table S1 and S2).
Development of GPS-MBA for the prediction of I-A
g7 and
HLA-DQ8 binding peptides
The series of GPS algorithms contain two computational
procedures of a scoring strategy and performance improvement
[27,28]. The scoring step has remained the same in all the versions
of the GPS algorithms, while the latter process is still in the process
Figure 1. A schematic diagram for the adapted Gibbs sampling
approach which was used to determine the nonamer core
peptides for I-A
g7 and HLA-DQ8 epitopes.
doi:10.1371/journal.pone.0033884.g001
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GPS 3.0 release, the performance improvement procedure is
comprised of the four sequential steps of k-means clustering, motif
length selection (MLS), WT and MaM [28]. Originally, we
proposed that such a training order could not be changed [28],
whereas our recent analysis instead suggests that such an order can
be shuffled if the training time is sufficient (Data not shown).
When the training data set is large, the k-means clustering
approach can be used to classify positive data into multiple groups
[28]. However, due to limited data available, this method was not
used in this work. The MLS approach was designed for
determining the motif length for optimal performance [28]. Since
experimental studies suggest that the nonamer core peptides are
essential for I-A
g7 and HLA-DQ8 recognition [9–11], this strategy
was also not adopted.
Taken together, the GPS algorithm has been improved, and the
performance improvement process only required the two steps of WT
and MaM. The training order was shuffled for better performance, and
the online service and software packages of GPS-MBA 1.0 were
implemented in JAVA. As an example, the prediction results for the
mouse Igk chain C region (UniProt ID: P01837) are shown (Figure 2).
Previously, a peptide in the mouse Igk Lc h a i n(
174ERQNGV
LNSWTDQDS
188, identical to 46–60 in the Igk chain C region) was
sequenced as an I-A
g7 epitope by MS/MS analysis [32]. In our results,
four potential I-A
g7 epitopes of
4APTVSIFPP
12,
49NGVLNSWTD
57,
68SSTLTLTKD
76,a n d
69STLTLTKDE
77 were predicted (Figure 2).
The
49NGVLNSWTD
57 nonamer gives complete coverage of the
experimental epitope (46–60), while the other three predicted hits are
available for further experimental investigation.
Performance evaluation and comparison
To evaluate the prediction performance and robustness of GPS-
MBA, LOO validation and 4-, 6-, 8-, 10-fold cross-validations
were performed (Figure 3A, 3B). ROC curves were drawn, while
the AROC values were 0.909 (LOO), 0.909 (4-fold), 0.904 (6-fold),
0.916 (8-fold) and 0.919 (10-fold) for mouse I-A
g7 (Figure 3A), and
0.921 (LOO), 0.933 (4-fold), 0.928 (6-fold), 0.937 (8-fold) and
0.931 (10-fold) for human HLA-DQ8 (Figure 3B). Since the results
of the 4-, 6-, 8- and 10-fold cross-validations were closely similar to
the LOO validation, the GPS-MBA 1.0 is evidently a stable and
robust predictor. The performance of the LOO validation was also
used for the cut-off setting and further comparison, and the three
thresholds of high, medium and low were selected with the Sp
values of 97%, 95% and 90%, respectively (Table 2). In addition,
given the highest MCC values, the medium thresholds were chosen
Figure 2. Screen snapshot of the GPS-MBA 1.0 software. The default threshold was chosen for MHC Class II I-A
g7 (Medium). As an example, the
prediction results for the Mouse Igk chain C region (UniProt ID: P01837) are shown.
doi:10.1371/journal.pone.0033884.g002
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g7 (0.1541) and HLA-DQ8 (0.1534),
respectively (Table 2).
To clearly demonstrate the superiority of GPS-MBA, we also
used the same data sets to evaluate the performances of
MHC2Pred [24,25] and RANKPEP [26]. We fixed the Sp values
of MHC2Pred and RANKPEP so as to be similar to GPS-MBA
and compared the Sn values (Table 2). For I-A
g7, when the Sp
value was ,97%, the Sn values of GPS-MBA, MHC2Pred and
RANKPEP were 62.89%, 23.58%, and 33.65%, respectively
(Table 2). Also, when the Sp value was ,95%, the Sn values of
GPS-MBA, MHC2Pred and RANKPEP were 71.70%, 32.70%,
and 45.91%, respectively (Table 2). Furthermore, when the Sp
Figure 3.The performance evaluation of GPS-MBA 1.0 and a comparison with other approaches. The LOO validation and 4-, 6-, 8- and
10-fold cross-validations were performed for (A) mouse I-A
g7 and (B) human HLA-DQ8, respectively. We compared the performance of GPS-MBA 1.0
with MHC2Pred and RANKPEP using the LOO validation for (C) I-A
g7 and (D) HLA-DQ8, respectively. We also performed a cross-evaluation by using
the HLA-DQ8 predictor in GPS-MBA to predict (C) I-A
g7 epitopes and (D) vice versa.
doi:10.1371/journal.pone.0033884.g003
Prediction of I-Ag7 and HLA-DQ8 Binding Peptides
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better than MHC2Pred (47.80%) and RANKPEP (64.15%)
(Table 2). Once again, for HLA-DQ8, the GPS-MBA perfor-
mance is still much better than the other two predictors. In
addition, ROC curves were drawn, showing that the AROC
values of the GPS-MBA were generally better than the other
approaches to I-A
g7 (Figure 3C) and HLA-DQ8 (Figure 3D).
Previous experimental studies suggested that the mouse I-A
g7
haplotype is equivalent to the human HLA-DQ8 linkage, and
exhibits a similar specificity for peptide recognition and binding
[1–6,8–11]. To investigate this viewpoint, we performed a cross-
evaluation using the HLA-DQ8 predictor in GPS-MBA to predict
I-A
g7 epitopes (Figure 3C) and vice versa (Figure 3D). In our results,
the cross-evaluation performance is closely similar to the LOO
validations (Figure 3C, 3D, and Table 2). Thus, we propose that
the binding patterns of I-A
g7 and HLA-DQ8 are highly similar
and conserved.
Prediction of potentially new I-A
g7 and HLA-DQ8
epitopes in T1D
Besides I-A
g7 and HLA-DQ8, certain other MHC class I and II
molecules are also implicated in T1D [1–7,17–19]. We collected 203
epitopes in 25 proteins from the scientific literature, with 70 MHC
class I epitopes, 84 MHC class II binding peptides and 49 epitopes for
which the MHC molecules are still undetermined (Table 3, Table
S3). Although at present there is a lack of experimental verification,
we propose that a number of these epitopes will also come to be
recognized by I-A
g7 and/or HLA-DQ8.
Table 2. Comparison of GPS-MBA 1.0 with other approaches.
Method Threshold Mouse I-A
g7 Human HLA-DQ8
Ac (%) Sn (%) Sp (%) MCC Ac (%) Sn (%) Sp (%) MCC
GPS-MBA High 96.88 62.89 97.01 0.2066 97.03 51.49 97.17 0.1575
Medium 94.96 71.70 95.05 0.1829 95.29 64.93 95.38 0.1553
Low 90.32 84.91 90.34 0.1530 90.11 81.34 90.13 0.1307
Cross
a 96.83 48.11 97.01 0.1569 97.04 50.00 97.18 0.1532
94.90 65.09 95.01 0.1646 95.21 60.45 95.32 0.1430
90.02 82.70 90.05 0.1461 90.09 80.60 90.12 0.1293
MHC2Pred 96.79 23.58 97.07 0.0736 96.90 17.16 97.14 0.0469
94.79 32.70 95.02 0.0768 94.98 26.87 95.19 0.0564
89.86 47.80 90.02 0.0763 90.19 44.03 90.33 0.0637
Rankpep 96.77 33.65 97.01 0.1075 96.84 30.60 97.04 0.0886
94.85 45.91 95.03 0.1130 95.13 40.30 95.30 0.0916
89.96 64.15 90.06 0.1093 90.02 64.18 90.10 0.0993
For the construction of the GPS-MBA 1.0 software, the three thresholds of high, medium and low were chosen. For comparison, we fixed the Sp values of GPS-MBA 1.0
to be identical or similar to other methods and compared the Sn values.
aCross, cross-evaluation by using the HLA-DQ8 predictor to predict I-A
g7 epitopes and vice versa.
doi:10.1371/journal.pone.0033884.t002
Table 3. The statistical data for the prediction of potentially new I-A
g7 and HLA-DQ8 epitopes in T1D.
Tool Data set Protein Epitope I-A
g7 HLA-DQ8 Either
Num.
a Per.
b Num. Per. Num. Per.
GPS-ARM Class I 15 70 1 1.43% 3 4.29% 4 5.71%
Class II 11 84 31 36.90% 28 33.33% 36 42.86%
Unknown 5 49 23 46.94% 19 38.78% 28 57.14%
Total 25 203 55 27.09% 50 24.63% 68 33.50%
MHC2Pred Class I 15 70 5 7.14% 2 2.86% 7 10.00%
Class II 11 84 25 29.76% 24 28.57% 42 50.00%
Unknown 5 49 22 44.90% 14 28.57% 29 59.18%
Total 31 203 52 25.62% 40 19.70% 78 38.42%
RANKPEP Class I 15 70 14 20.00% 3 4.29% 15 21.43%
Class II 11 84 42 50.00% 24 28.57% 48 57.14%
Unknown 5 49 28 57.14% 18 36.73% 33 67.35%
Total 31 203 84 41.38% 45 22.17% 96 47.29%
aNum., the number of manually collected epitopes predicted with core 9-mers.
bPer., percentiles.
doi:10.1371/journal.pone.0033884.t003
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g7 and HLA-DQ8 epitopes, we used
GPS-MBA 1.0 with the default thresholds. In total, 68 epitopes
were predicted to interact with either I-A
g7 or HLA-DQ8 (33.5%)
(Table 3). Also, the prediction results of MHC2Pred [24,25] and
RANKPEP [26] were present with default thresholds (Table 3). In
particular, the prediction performance of GPS-MBA 1.0 is much
poorer in terms of the MHC class I epitopes, such that only one
and three epitopes were predicted as I-A
g7 and HLA-DQ8 binding
peptides, respectively (Table 3). However, GPS-MBA 1.0
displayed a considerably effective performance for MHC class II
epitopes by predicting 31 I-A
g7 and 28 HLA-DQ8 binding
peptides (Table 3). Also, the distributions of results from
MHC2Pred and RANKPEP are similar (Table 3). In this regard,
the sequence profiles of MHC class I and II are quite different,
whereas GPS-MBA, MHC2Pred and RANKPEP have the
Table 4. The statistical results of the TEDB 1.0 database.
Organism Protein
Known
epitopes Predicted epitopes Total
I-A
g7 HLA-DQ8 Either
H. Sapiens 20 262 553 527 773 944
M. musculus 180 285 4,627 4,701 6,587 6,485
R.
norvegicus
13 18 331 382 505 503
Others 32 58 801 785 1,123 1,105
Total 245 623 6,312 6,395 8,988 9,037
doi:10.1371/journal.pone.0033884.t004
Figure 4. The search options for the TEDB 1.0 database. (A) Users are able to simply input ‘RAN’ and select ‘‘Gene Name’’ for querying. (B) The
results are shown in a tabular format. Users can then click on the TEDB ID (TEDB-HS-00015) to visualize the detailed information. (C) The detailed
information on human RAN. The experimentally identified and predicted epitopes are presented.
doi:10.1371/journal.pone.0033884.g004
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epitopes. In particular, GPS-MBA, MHC2Pred and RANKPEP
predicted 28 (57.14%), 29 (59.18%) and 33 (67.35%) unannotated
epitopes as having either I-A
g7 or HLA-DQ8 binding peptides
(Table 3). Taken together, this analysis suggests that there are
additional bona fide I-A
g7 and HLA-DQ8 epitopes which still
remain to be identified, and these prediction results comprise a
useful resource for further experimental investigation. The detailed
prediction results of GPS-MBA are shown in Table S1.
The development and usage of TEDB 1.0
To provide an integrative platform for computational analysis of
the T1D epitopes, all of the experimental identified T1D-associated
antigens together with their epitopes were collected for the
development of TEDB (Table 4). Also, we used GPS-MBA 1.0 at
the default threshold to predict potential I-A
g7 or HLA-DQ8 epitopes
in 245 antigens (Table 4). In addition, the prediction results of
MHC2Pred and RANKPEP were also included in the TEDB 1.0.
TEDB 1.0 was developed in a user-friendly manner. The search
option (http://mba.biocuckoo.org/database.php) provides an
interface for querying the TEDB database with one or several
keywords such as TEDB ID, MHC Type, or UniProt Accession,
etc (Figure 4A). We also provided three advance options, including
advance search, browse and BLAST search (Figure 4A). For
example, if the keyword ‘RAN’ is inputted and submitted
(Figure 4A), the result is shown in a tabular format, with the
features of TEDB ID, UniProt accession, and protein/gene
names/aliases (Figure 4B). By clicking on the TEDB ID (TEDB-
HS-00015), the detailed information on human RAN is shown
(Figure 4C). The experimentally identified epitopes and predicted
I-A
g7 and HLA-DQ8 binding peptides are provided, while the
protein sequence, Gene Ontology annotation, domain organiza-
tion, molecular weight and computed/theoretical Ip are also
provided (Figure 4C).
Discussion
T1D, also termed Insulin-dependent diabetes mellitus (IDDM)
or juvenile diabetes, is a chronic metabolic disorder and
autoimmune disease that takes a heavy toll world-wide [1–7,33].
Currently, it is estimated that approximately 70,000 children
develop T1D per year, ,30,000 of which cases are in the United
States, and an annual global increase of ,3% [4,5,33]. Although a
number of immunotherapeutic and regenerative approaches have
been developed, the effective prevention and treatment of T1D are
both still a great challenge [1–7,33]. Recent advances in the
development of antigen-based ‘‘tolerogenic’’ immunotherapy have
provided a great opportunity for treating T1D with a high degree
of selectivity, while two investigations are still ongoing as clinical
trials, and the outcome is uncertain [1–7,12,33]. In this regard, the
Identification of T1D-speicific epitopes is needed for further
experimental and biomedical design.
Although a number of computational analyses were carried out
for the prediction of the I-A
g7 or HLA-DQ8 epitopes, the online
services have been not available over the internet [20–23]. Again,
although the two integrative tools of MHC2Pred and RANKPEP
do contain predictors of I-A
g7 and HLA-DQ8, they were actually
designed for the general prediction of MHC class I and/or II
epitopes [24–26]. Thus, they might exhibit a sensitive performance
for other MHC molecules, and yet not I-A
g7 and/or HLA-DQ8.
In this study, we focused on the prediction of I-A
g7 and HLA-DQ8
by constructing the GPS-MBA software package. By comparison,
the performance of GPS-MBA is much better than MHC2Pred
and RANKPEP (Table 2, Figure 3C, 3D).
Originally, the series of GPS algorithms were developed for the
prediction of PTM sites in proteins [27,28], and this is the first use
of the algorithm for MHC epitopes. The major difference between
PTM sites and MHC epitopes is that the PTM site positions are
anchored by the middle residues, while the lengths and positions of
the MHC epitopes are promiscuous and difficult to fix. In this
regard, the MHC epitope core sequences of defined length must
be determined prior to training. Originally, the Gibbs sampling
method was designed for detecting short conserved motifs from
multiple DNA or protein sequences [29–31]. By utilizing the
position-specific scoring matrices (PSSMs), the amino acids
frequencies were counted in the foreground and background data
sets, respectively. In this procedure, the ratio of the pattern
probability to the background probability was calculated and
improved by sampling, until convergence was attained [29–31].
However, the average similarity score, but not the frequency ratio,
was calculated for further sampling in our analysis. The 9-mer
core peptides were determined by this approach for I-A
g7 and
HLA-DQ8, respectively.
Here, we used the WebLogo server [34] to analyze the sequence
profiles of the core nonamers for I-A
g7 (Figure 5A) and HLA-DQ8
(Figure 5B), respectively. Previously, experimental studies based on
limited epitopes had suggested that P4, P6 and P9 are three
conserved positions, while P1 is a degenerate position [9–11].
However, our results suggest that P9 is the most informative
position, along with a less the comparatively weakly conserved
position of P8 (Figure 5A, 5B). P4 is weakly conserved in I-A
g7 core
nonamers (Figure 5A) and not conserved in HLA-DQ8 (Figure 5B).
Although the sequence logo of I-A
g7 is not evidently similar to
HLA-DQ8, our cross-evaluation results indicate that I-A
g7 and
HLA-DQ8 are able to recognize similar peptide profiles (Table 2,
Figure 3C, 3D). We speculated that whether most of the HLA-
DQ8 epitopes would also be I-A
g7 binding peptides in the training
data set, since the NOD mouse is the best model for T1D.
However, there are only 24 epitopes in the original data set which
interact with both I-A
g7 (24/318) and HLA-DQ8 (24/134). Again,
in the non-redundant core nonamers, only 22 9-mer peptides were
found to bind with both I-A
g7 and HLA-DQ8. Based on these
Figure 5. The sequence logos of the core nonamers for (A) I-A
g7
and (B) HLA-DQ8.
doi:10.1371/journal.pone.0033884.g005
Prediction of I-Ag7 and HLA-DQ8 Binding Peptides
PLoS ONE | www.plosone.org 8 March 2012 | Volume 7 | Issue 3 | e33884results, we propose that the sequence profile of I-A
g7 is intrinsically
similar to that of HLA-DQ8.
In addition to the predictions of GPS-MBA, all of the
experimentally validated T1D-associated epitopes were collected
in the online database of TEDB 1.0. The ab initio predictions with
GPS-MBA were also integrated into TEDB. Thus, such an
integrative platform should prove to be useful for experimentalists.
We believe that computational analysis, together with subsequent
experimental identification, will help advance the study of T1D
into a new and highly productive phase.
Supporting Information
Table S1 The core nonamers of the mouse I-A
g7
epitopes. a. Epitope, the original epitopes; b. Position, the
positions of core nonamers in the protein sequences; c. Core
nonamer, the finally aligned core nonamers were marked in red; d.
The protein sequence was retrieved from the UniParc (UniProt
Archive) Database (http://www.uniprot.org/help/uniparc).
(XLS)
Table S2 The core nonamers of the human HLA-DQ8
epitopes.
(XLS)
Table S3 From the scientific literature, we collected 203
epitopes in 25 proteins, with 70 MHC class I epitopes, 84
MHC class II binding peptides, and 49 epitopes for
which the MHC molecules are still unknown. The detailed
prediction results of GPS-ARM were provided. a. UniProt, the
UniProt accession numbers of T1D antigens; b. Pos., the position
of the original known epitopes; c. Peptide, the experimentally
identified epitopes; d. MHC Type, the experimentally identified
MHC molecules that recognize the epitopes; e. Pre. Pos., the
predicted position of the binding peptides; f. Pre. Peptide, the
predicted core nonamers; g. Pre. Type, the predicted MHC
molecules of I-A
g7 and HLA-DQ8 that potentially recognize the
core 9-mers.
(XLS)
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